Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures

Launched by MARMARA UNIVERSITY · Dec 3, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well a new treatment plan can help postmenopausal women with osteoporosis who have already had multiple fractures. The researchers want to find out if adding a medication called romosozumab to the ongoing treatment with denosumab can help prevent further fractures. They will compare three different treatment options: continuing with denosumab, switching entirely to romosozumab, or adding romosozumab while still taking denosumab. The trial aims to see which approach is best and whether combining these two medications causes any complications.

To be eligible for this trial, participants need to be women aged 55 to 85 who are postmenopausal and have been receiving denosumab treatment for at least two years. Those with certain health conditions, such as heart disease or kidney problems, cannot participate. Women in the study will visit the clinic every three months, have blood tests, and undergo bone density checks to monitor their progress. They will also keep a diary to record any symptoms they experience during the trial. This study is not yet recruiting participants, but it represents an important step in finding better ways to manage osteoporosis in women at high risk for fractures.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Postmenopausal Women
• • Patients with Osteoporosis
• • Patients aged between 55 and 85 years old
• Exclusion Criteria:
• • Patient with history of Serebrovascular diseases
• • Patient with history of Miyocardial Infarction
• • Patients who have calcium metabiolism disturbances
• • Patients with chronic kidney diseases
• • Patient with history of allergic reactions to denosumab or romosozumab